Dysport Type A (2x500Units)

Dysport Type A for sale was developed in the United Kingdom in the early 1990s to successfully treat a number of neurological and ophthalmic conditions.

The active substance in Dysport® is a botulinum neurotoxin type A complex, which acts at the level of the neuromuscular junction in the targeted muscle.

• When treating, Dysport is reconstituted with 2.5ml of sodium chloride injection BP (0.9%) to yield a solution containing 10 units of Dysport per 0.05 ml. Dysport is administered by intramuscular or subcutaneous injection. Dysport is reconstituted with 1.0ml of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per ml of Dysport. Dysport is administered by intramuscular injection into the five muscles detailed above when treating arm spasticity.

• When treating paediatric cerebral palsy spasticity, Dysport is reconstituted with 1.0ml of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per ml of Dysport. Dysport Type A is administered by intramuscular injection into the calf muscles when treating spasticity. 
• When treating spasmodic torticollis Dysport is reconstituted with 1ml of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per ml of Dysport. Dysport is administered by intramuscular injection as above when treating spasmodic torticollis. 
• When treating blepharospasm and hemifacial spasm Dysport is reconstituted with 2.5ml of sodium chloride injection BP (0.9%) to yield a solution containing 200 units per ml of Dysport Type A. Dysport is administered by subcutaneous injection medially and laterally into the junction between the preseptal and orbital parts of both the upper and lower orbicularis oculi muscles of the eyes. 
• When treating axillary hyperhidrosis, Dysport is reconstituted with 2.5ml of sodium chloride solution (0.9%) to yield a solution containing 200 units per ml of Dysport.